25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

ATNM (Actinium Pharmaceuticals Inc) Stock Analysis
Buy, Hold or Sell?

Let's analyze Actinium Pharmaceuticals Inc together

I guess you are interested in Actinium Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – Actinium Pharmaceuticals Inc’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – Actinium Pharmaceuticals Inc’s Price Targets

I'm going to help you getting a better view of Actinium Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Actinium Pharmaceuticals Inc

I send you an email if I find something interesting about Actinium Pharmaceuticals Inc.

1. Quick Overview

1.1. Quick analysis of Actinium Pharmaceuticals Inc (30 sec.)










1.2. What can you expect buying and holding a share of Actinium Pharmaceuticals Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
10.0%

What is your share worth?

Current worth
$1.05
Expected worth in 1 year
$0.93
How sure are you?
30.0%

+ What do you gain per year?

Total Gains per Share
$-0.12
Return On Investment
-7.5%

For what price can you sell your share?

Current Price per Share
$1.55
Expected price per share
$1.0292 - $2.41
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Actinium Pharmaceuticals Inc (5 min.)




Live pricePrice per Share (EOD)
$1.55
Intrinsic Value Per Share
$-6.86 - $-6.42
Total Value Per Share
$-5.81 - $-5.37

2.2. Growth of Actinium Pharmaceuticals Inc (5 min.)




Is Actinium Pharmaceuticals Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$32.7m$47.5m-$7.8m-19.9%

How much money is Actinium Pharmaceuticals Inc making?

Current yearPrevious yearGrowGrow %
Making money-$9.5m-$12.2m$2.6m27.7%
Net Profit Margin0.0%-2,877.8%--

How much money comes from the company's main activities?

2.3. Financial Health of Actinium Pharmaceuticals Inc (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#481 / 892

Most Revenue
#727 / 892

Most Profit
#487 / 892

Most Efficient
#259 / 892
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Actinium Pharmaceuticals Inc?

Welcome investor! Actinium Pharmaceuticals Inc's management wants to use your money to grow the business. In return you get a share of Actinium Pharmaceuticals Inc.

First you should know what it really means to hold a share of Actinium Pharmaceuticals Inc. And how you can make/lose money.

Speculation

The Price per Share of Actinium Pharmaceuticals Inc is $1.55. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Actinium Pharmaceuticals Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Actinium Pharmaceuticals Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $1.05. Based on the TTM, the Book Value Change Per Share is $-0.03 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.24 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Actinium Pharmaceuticals Inc.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.21-13.8%-0.31-19.8%-0.39-25.2%-0.32-20.7%-0.27-17.3%-0.20-12.7%
Usd Book Value Change Per Share-0.17-11.3%-0.03-1.9%-0.24-15.6%-0.11-7.0%0.042.8%0.031.8%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.17-11.3%-0.03-1.9%-0.24-15.6%-0.11-7.0%0.042.8%0.031.8%
Usd Price Per Share1.26-4.59-6.97-6.18-6.13-3.65-
Price to Earnings Ratio-1.48--3.72--4.55--4.96--6.18--3.82-
Price-to-Total Gains Ratio-7.21--2,619.53--32.32--894.00--602.01--310.16-
Price to Book Ratio1.20-3.39-4.53-3.68-3.47-2.90-
Price-to-Total Gains Ratio-7.21--2,619.53--32.32--894.00--602.01--310.16-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.55
Number of shares645
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.030.04
Usd Total Gains Per Share-0.030.04
Gains per Quarter (645 shares)-18.7228.03
Gains per Year (645 shares)-74.87112.14
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-75-850112102
20-150-1600224214
30-225-2350336326
40-299-3100448438
50-374-3850561550
60-449-4600673662
70-524-5350785774
80-599-6100897886
90-674-68501009998
100-749-760011211110

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%1.039.00.02.5%4.069.00.05.5%
Book Value Change Per Share1.03.00.025.0%2.010.00.016.7%6.014.00.030.0%12.028.00.030.0%17.055.01.023.3%
Dividend per Share0.00.04.00.0%0.00.012.00.0%4.00.016.020.0%4.00.036.010.0%4.00.069.05.5%
Total Gains per Share1.03.00.025.0%2.010.00.016.7%6.014.00.030.0%12.028.00.030.0%17.055.01.023.3%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Actinium Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.175-0.029-83%-0.241+38%-0.109-38%0.043-502%0.028-729%
Book Value Per Share--1.0501.271-17%1.525-31%1.693-38%1.762-40%1.126-7%
Current Ratio--9.1449.734-6%10.514-13%11.399-20%12.239-25%8.584+7%
Debt To Asset Ratio--0.5740.531+8%0.492+17%0.444+29%0.324+77%0.290+98%
Debt To Equity Ratio--1.3471.140+18%0.982+37%0.874+54%0.641+110%0.517+161%
Dividend Per Share----0%-0%-0%0.000-100%0.000-100%
Enterprise Value--68069834.000179039670.750-62%258415933.250-74%240683818.417-72%242218191.773-72%146316546.534-53%
Eps---0.213-0.306+44%-0.391+83%-0.321+50%-0.268+26%-0.197-7%
Ev To Ebitda Ratio---2.331-4.329+86%-5.162+121%-6.085+161%-7.867+238%-5.095+119%
Free Cash Flow Per Share---0.184-0.265+44%-0.381+106%-0.193+5%-0.185+0%-0.175-5%
Free Cash Flow To Equity Per Share---0.184-0.030-84%-0.261+42%-0.013-93%0.102-281%0.053-446%
Gross Profit Margin--1.0001.006-1%1.0000%1.0020%1.0010%1.0010%
Intrinsic Value_10Y_max---6.417----------
Intrinsic Value_10Y_min---6.855----------
Intrinsic Value_1Y_max---0.693----------
Intrinsic Value_1Y_min---0.763----------
Intrinsic Value_3Y_max---2.044----------
Intrinsic Value_3Y_min---2.240----------
Intrinsic Value_5Y_max---3.349----------
Intrinsic Value_5Y_min---3.648----------
Market Cap48353645.000+19%39306834.000143267170.750-73%217357433.250-82%192868651.750-80%191270641.773-79%113870104.334-65%
Net Profit Margin----0%-28.7780%-48.6820%-49.3720%-24.6860%
Operating Margin----0%-31.9230%-52.0360%-51.4910%-25.7460%
Operating Ratio----0%32.173-100%53.241-100%52.712-100%26.356-100%
Pb Ratio1.476+19%1.2003.393-65%4.527-73%3.679-67%3.470-65%2.895-59%
Pe Ratio-1.817-23%-1.477-3.718+152%-4.554+208%-4.964+236%-6.183+319%-3.822+159%
Price Per Share1.550+19%1.2604.593-73%6.968-82%6.183-80%6.131-79%3.650-65%
Price To Free Cash Flow Ratio-2.102-23%-1.709-4.610+170%-4.630+171%-5.258+208%-6.686+291%-4.276+150%
Price To Total Gains Ratio-8.872-23%-7.212-2619.534+36221%-32.319+348%-894.004+12296%-602.011+8247%-310.164+4201%
Quick Ratio--8.9479.590-7%10.147-12%11.141-20%11.977-25%8.365+7%
Return On Assets---0.087-0.113+31%-0.131+52%-0.106+23%-0.127+47%-0.222+156%
Return On Equity---0.203-0.241+18%-0.260+28%-0.205+1%-0.249+23%-0.355+75%
Total Gains Per Share---0.175-0.029-83%-0.241+38%-0.109-38%0.043-502%0.028-729%
Usd Book Value--32758000.00039664500.000-17%47561750.000-31%52804916.667-38%54963200.000-40%35123299.775-7%
Usd Book Value Change Per Share---0.175-0.029-83%-0.241+38%-0.109-38%0.043-502%0.028-729%
Usd Book Value Per Share--1.0501.271-17%1.525-31%1.693-38%1.762-40%1.126-7%
Usd Dividend Per Share----0%-0%-0%0.000-100%0.000-100%
Usd Enterprise Value--68069834.000179039670.750-62%258415933.250-74%240683818.417-72%242218191.773-72%146316546.534-53%
Usd Eps---0.213-0.306+44%-0.391+83%-0.321+50%-0.268+26%-0.197-7%
Usd Free Cash Flow---5751000.000-8270750.000+44%-11872000.000+106%-6024416.667+5%-5758100.000+0%-5459345.400-5%
Usd Free Cash Flow Per Share---0.184-0.265+44%-0.381+106%-0.193+5%-0.185+0%-0.175-5%
Usd Free Cash Flow To Equity Per Share---0.184-0.030-84%-0.261+42%-0.013-93%0.102-281%0.053-446%
Usd Market Cap48353645.000+19%39306834.000143267170.750-73%217357433.250-82%192868651.750-80%191270641.773-79%113870104.334-65%
Usd Price Per Share1.550+19%1.2604.593-73%6.968-82%6.183-80%6.131-79%3.650-65%
Usd Profit---6652000.000-9560750.000+44%-12204500.000+83%-9922833.333+49%-8303150.000+25%-7088880.350+7%
Usd Revenue----0%20250.000-100%102083.333-100%118450.000-100%59225.000-100%
Usd Total Gains Per Share---0.175-0.029-83%-0.241+38%-0.109-38%0.043-502%0.028-729%
 EOD+5 -3MRQTTM+12 -21YOY+19 -153Y+13 -225Y+13 -2410Y+10 -27

3.3 Fundamental Score

Let's check the fundamental score of Actinium Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-1.817
Price to Book Ratio (EOD)Between0-11.476
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than18.947
Current Ratio (MRQ)Greater than19.144
Debt to Asset Ratio (MRQ)Less than10.574
Debt to Equity Ratio (MRQ)Less than11.347
Return on Equity (MRQ)Greater than0.15-0.203
Return on Assets (MRQ)Greater than0.05-0.087
Total3/10 (30.0%)

3.4 Technical Score

Let's check the technical score of Actinium Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5060.606
Ma 20Greater thanMa 501.311
Ma 50Greater thanMa 1001.316
Ma 100Greater thanMa 2001.280
OpenGreater thanClose1.550
Total2/5 (40.0%)

4. In-depth Analysis

4.1 About Actinium Pharmaceuticals Inc

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company advances two clinical stage product candidates, Actimab-A, to treat patients with myeloid malignancies including acute myeloid leukemia and myelodysplastic syndromes; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T for various blood cancer indications and gene therapies for non-malignant hematologic disorders such as sickle cell disease. It also develops ATNM-400, a preclinical non-prostate specific-membrane antigen targeting radiotherapy utilizing the Actinium-225 radioisotope for patients with prostate cancer. In addition, the company's Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). Further, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies, and its research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company is based in New York, New York.

Fundamental data was last updated by Penke on 2025-04-20 23:39:05.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ Actinium Pharmaceuticals Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compareΒ Actinium Pharmaceuticals Inc to theΒ Biotechnology industry mean.
  • A Net Profit Margin of 0.0%Β means thatΒ $0.00 for each $1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Actinium Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-2,877.8%+2,877.8%
TTM-5Y-4,937.2%+4,937.2%
5Y-4,937.2%10Y-2,468.6%-2,468.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--93.6%+93.6%
TTM--180.4%+180.4%
YOY-2,877.8%-196.9%-2,680.9%
3Y-4,868.2%-244.6%-4,623.6%
5Y-4,937.2%-350.0%-4,587.2%
10Y-2,468.6%-486.0%-1,982.6%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ Actinium Pharmaceuticals Inc is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ Actinium Pharmaceuticals Inc to theΒ Biotechnology industry mean.
  • -8.7% Return on Assets means thatΒ Actinium Pharmaceuticals Inc generatedΒ $-0.09 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Actinium Pharmaceuticals Inc:

  • The MRQ is -8.7%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -11.3%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-8.7%TTM-11.3%+2.6%
TTM-11.3%YOY-13.1%+1.8%
TTM-11.3%5Y-12.7%+1.4%
5Y-12.7%10Y-22.2%+9.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-8.7%-11.7%+3.0%
TTM-11.3%-12.0%+0.7%
YOY-13.1%-11.7%-1.4%
3Y-10.6%-12.1%+1.5%
5Y-12.7%-12.9%+0.2%
10Y-22.2%-14.5%-7.7%
4.3.1.3. Return on Equity

Shows how efficient Actinium Pharmaceuticals Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ Actinium Pharmaceuticals Inc to theΒ Biotechnology industry mean.
  • -20.3% Return on Equity means Actinium Pharmaceuticals Inc generated $-0.20Β for eachΒ $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Actinium Pharmaceuticals Inc:

  • The MRQ is -20.3%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -24.1%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-20.3%TTM-24.1%+3.8%
TTM-24.1%YOY-26.0%+1.9%
TTM-24.1%5Y-24.9%+0.8%
5Y-24.9%10Y-35.5%+10.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-20.3%-15.5%-4.8%
TTM-24.1%-15.8%-8.3%
YOY-26.0%-15.5%-10.5%
3Y-20.5%-17.7%-2.8%
5Y-24.9%-18.4%-6.5%
10Y-35.5%-20.8%-14.7%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Actinium Pharmaceuticals Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient Actinium Pharmaceuticals Inc is operatingΒ .

  • Measures how much profit Actinium Pharmaceuticals Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ Actinium Pharmaceuticals Inc to theΒ Biotechnology industry mean.
  • An Operating Margin of 0.0%Β means the company generated $0.00 Β for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Actinium Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-3,192.3%+3,192.3%
TTM-5Y-5,149.1%+5,149.1%
5Y-5,149.1%10Y-2,574.6%-2,574.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--187.8%+187.8%
TTM--285.2%+285.2%
YOY-3,192.3%-208.0%-2,984.3%
3Y-5,203.6%-247.4%-4,956.2%
5Y-5,149.1%-360.9%-4,788.2%
10Y-2,574.6%-464.7%-2,109.9%
4.3.2.2. Operating Ratio

Measures how efficient Actinium Pharmaceuticals Inc is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Actinium Pharmaceuticals Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY32.173-32.173
TTM-5Y52.712-52.712
5Y52.71210Y26.356+26.356
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.126-2.126
TTM-3.019-3.019
YOY32.1732.886+29.287
3Y53.2413.487+49.754
5Y52.7124.862+47.850
10Y26.3566.533+19.823
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Actinium Pharmaceuticals Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Actinium Pharmaceuticals Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Biotechnology industry mean).
  • A Current Ratio of 9.14Β means the company has $9.14 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Actinium Pharmaceuticals Inc:

  • The MRQ is 9.144. The company is very able to pay all its short-term debts. +2
  • The TTM is 9.734. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ9.144TTM9.734-0.590
TTM9.734YOY10.514-0.780
TTM9.7345Y12.239-2.505
5Y12.23910Y8.584+3.655
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ9.1443.588+5.556
TTM9.7343.910+5.824
YOY10.5144.280+6.234
3Y11.3994.801+6.598
5Y12.2395.833+6.406
10Y8.5846.244+2.340
4.4.3.2. Quick Ratio

Measures if Actinium Pharmaceuticals Inc is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ Actinium Pharmaceuticals Inc to theΒ Biotechnology industry mean.
  • A Quick Ratio of 8.95Β means the company can pay off $8.95 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Actinium Pharmaceuticals Inc:

  • The MRQ is 8.947. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 9.590. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ8.947TTM9.590-0.642
TTM9.590YOY10.147-0.558
TTM9.5905Y11.977-2.387
5Y11.97710Y8.365+3.612
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ8.9472.848+6.099
TTM9.5903.430+6.160
YOY10.1474.128+6.019
3Y11.1414.685+6.456
5Y11.9775.882+6.095
10Y8.3656.550+1.815
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Actinium Pharmaceuticals Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of Actinium Pharmaceuticals IncΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ Actinium Pharmaceuticals Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.57Β means that Actinium Pharmaceuticals Inc assets areΒ financed with 57.4% credit (debt) and the remaining percentage (100% - 57.4%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of Actinium Pharmaceuticals Inc:

  • The MRQ is 0.574. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.531. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.574TTM0.531+0.043
TTM0.531YOY0.492+0.039
TTM0.5315Y0.324+0.207
5Y0.32410Y0.290+0.035
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.5740.342+0.232
TTM0.5310.341+0.190
YOY0.4920.330+0.162
3Y0.4440.330+0.114
5Y0.3240.359-0.035
10Y0.2900.382-0.092
4.5.4.2. Debt to Equity Ratio

Measures ifΒ Actinium Pharmaceuticals Inc is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ Actinium Pharmaceuticals Inc to theΒ Biotechnology industry mean.
  • A Debt to Equity ratio of 134.7% means that company has $1.35 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Actinium Pharmaceuticals Inc:

  • The MRQ is 1.347. The company is able to pay all its debts with equity. +1
  • The TTM is 1.140. The company is able to pay all its debts with equity. +1
Trends
Current periodCompared to+/- 
MRQ1.347TTM1.140+0.207
TTM1.140YOY0.982+0.158
TTM1.1405Y0.641+0.500
5Y0.64110Y0.517+0.124
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.3470.408+0.939
TTM1.1400.427+0.713
YOY0.9820.406+0.576
3Y0.8740.440+0.434
5Y0.6410.449+0.192
10Y0.5170.506+0.011
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every $1 in earnings Actinium Pharmaceuticals Inc generates.

  • Above 15 is considered overpriced butΒ always compareΒ Actinium Pharmaceuticals Inc to theΒ Biotechnology industry mean.
  • A PE ratio of -1.48 means the investor is paying $-1.48Β for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Actinium Pharmaceuticals Inc:

  • The EOD is -1.817. Based on the earnings, the company is expensive. -2
  • The MRQ is -1.477. Based on the earnings, the company is expensive. -2
  • The TTM is -3.718. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.817MRQ-1.477-0.340
MRQ-1.477TTM-3.718+2.241
TTM-3.718YOY-4.554+0.836
TTM-3.7185Y-6.183+2.465
5Y-6.18310Y-3.822-2.361
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.817-1.965+0.148
MRQ-1.477-2.553+1.076
TTM-3.718-3.216-0.502
YOY-4.554-3.402-1.152
3Y-4.964-4.122-0.842
5Y-6.183-6.344+0.161
10Y-3.822-7.002+3.180
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Actinium Pharmaceuticals Inc:

  • The EOD is -2.102. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -1.709. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -4.610. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.102MRQ-1.709-0.393
MRQ-1.709TTM-4.610+2.902
TTM-4.610YOY-4.630+0.019
TTM-4.6105Y-6.686+2.076
5Y-6.68610Y-4.276-2.411
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.102-2.660+0.558
MRQ-1.709-3.481+1.772
TTM-4.610-4.076-0.534
YOY-4.630-4.319-0.311
3Y-5.258-5.522+0.264
5Y-6.686-8.511+1.825
10Y-4.276-9.706+5.430
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ Actinium Pharmaceuticals Inc is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Biotechnology industry mean).
  • A PB ratio of 1.20 means the investor is paying $1.20Β for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Actinium Pharmaceuticals Inc:

  • The EOD is 1.476. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.200. Based on the equity, the company is underpriced. +1
  • The TTM is 3.393. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD1.476MRQ1.200+0.276
MRQ1.200TTM3.393-2.193
TTM3.393YOY4.527-1.134
TTM3.3935Y3.470-0.077
5Y3.47010Y2.895+0.575
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.4761.828-0.352
MRQ1.2002.268-1.068
TTM3.3932.425+0.968
YOY4.5272.517+2.010
3Y3.6792.904+0.775
5Y3.4703.775-0.305
10Y2.8954.380-1.485
4.6.2. Total Gains per Share

2.4. Latest News of Actinium Pharmaceuticals Inc

Does Actinium Pharmaceuticals Inc still have the same value as the quarterly reports suggest? Recent changes may be an indication that the value of the company is changing. Read the news from Actinium Pharmaceuticals Inc to keep up to date. Note: the news is often already included in the price.

DateTitleRead
2025-05-02
19:48
Class Action Filed Against Actinium Pharmaceuticals, Inc. (ATNM) Seeking Recovery for Investors – Contact Levi & KorsinskyRead
2025-04-29
16:50
ATNM Investors Have the Opportunity to Lead the Actinium Securities Fraud Lawsuit with Faruqi & Faruqi, LLPRead
2025-04-29
16:21
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Actinium Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - ATNMRead
2025-04-28
18:27
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 27, 2025 in Actinium Lawsuit – ATNMRead
2025-04-26
16:25
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of ActiniumRead
2025-04-25
22:00
ATNM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Actinium Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitRead
2025-04-25
18:02
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Actinium Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - ATNMRead
2025-04-24
18:23
Investors who lost money on Actinium Pharmaceuticals, Inc. (ATNM) should contact Levi & Korsinsky about pending Class Action - ATNMRead
2025-04-23
19:12
Lost Money on Actinium Pharmaceuticals, Inc. (ATNM)? Join Class Action Suit Seeking Recovery – Contact The Gross Law FirmRead
2025-04-23
16:10
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of ActiniumRead

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Actinium Pharmaceuticals Inc.

3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2024-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets76,899
Total Liabilities44,141
Total Stockholder Equity32,758
 As reported
Total Liabilities 44,141
Total Stockholder Equity+ 32,758
Total Assets = 76,899

Assets

Total Assets76,899
Total Current Assets74,506
Long-term Assets2,393
Total Current Assets
Cash And Cash Equivalents 72,904
Other Current Assets 1,602
Total Current Assets  (as reported)74,506
Total Current Assets  (calculated)74,506
+/-0
Long-term Assets
Property Plant Equipment 2,069
Long-term Assets Other 324
Long-term Assets  (as reported)2,393
Long-term Assets  (calculated)2,393
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities8,148
Long-term Liabilities35,993
Total Stockholder Equity32,758
Total Current Liabilities
Short-term Debt 580
Other Current Liabilities 7,568
Total Current Liabilities  (as reported)8,148
Total Current Liabilities  (calculated)8,148
+/-0
Long-term Liabilities
Capital Lease Obligations 1,573
Long-term Liabilities  (as reported)35,993
Long-term Liabilities  (calculated)1,573
+/- 34,420
Total Stockholder Equity
Common Stock31
Retained Earnings -375,826
Other Stockholders Equity 408,553
Total Stockholder Equity (as reported)32,758
Total Stockholder Equity (calculated)32,758
+/-0
Other
Capital Stock31
Cash and Short Term Investments 72,904
Common Stock Shares Outstanding 30,070
Liabilities and Stockholders Equity 76,899
Net Debt -71,331
Net Invested Capital 32,758
Net Working Capital 66,358
Property Plant and Equipment Gross 2,960
Short Long Term Debt Total 1,573



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-312006-12-312006-09-30
> Total Assets 
0
0
0
0
6
6
2
2
2
2
2
2
2
2
1
35
0
0
0
0
0
0
0
0
2,831
5,789
3,357
5,735
4,050
5,766
6,560
15,447
12,598
7,569
20,055
26,330
25,050
26,588
23,344
21,573
17,262
22,529
18,245
12,977
21,721
18,337
28,141
22,585
15,702
14,889
12,235
21,819
16,318
11,670
8,364
55,958
50,527
66,397
75,097
84,454
84,479
80,388
74,562
121,800
116,816
114,192
102,026
99,051
88,944
81,445
88,352
89,861
82,114
76,899
76,89982,11489,86188,35281,44588,94499,051102,026114,192116,816121,80074,56280,38884,47984,45475,09766,39750,52755,9588,36411,67016,31821,81912,23514,88915,70222,58528,14118,33721,72112,97718,24522,52917,26221,57323,34426,58825,05026,33020,0557,56912,59815,4476,5605,7664,0505,7353,3575,7892,8310000000035122222222660000
   > Total Current Assets 
0
0
0
0
6
6
2
2
2
2
2
2
2
2
1
35
0
0
0
0
0
0
0
0
2,828
5,786
3,357
5,735
4,043
5,752
6,546
15,279
12,423
7,407
19,919
26,210
24,920
26,481
23,179
21,413
17,121
22,390
18,119
12,466
21,215
17,839
27,647
22,084
15,157
14,330
10,265
19,945
14,551
10,088
6,806
54,508
49,180
64,925
73,747
83,171
83,261
79,749
74,053
118,297
113,423
110,942
98,546
95,537
85,596
78,263
85,373
87,068
79,520
74,506
74,50679,52087,06885,37378,26385,59695,53798,546110,942113,423118,29774,05379,74983,26183,17173,74764,92549,18054,5086,80610,08814,55119,94510,26514,33015,15722,08427,64717,83921,21512,46618,11922,39017,12121,41323,17926,48124,92026,21019,9197,40712,42315,2796,5465,7524,0435,7353,3575,7862,8280000000035122222222660000
       Cash And Cash Equivalents 
0
0
0
0
6
6
2
2
2
2
2
2
2
2
1
0
0
0
0
0
0
0
0
0
2,567
5,619
3,240
5,650
3,990
5,533
5,878
14,671
11,751
6,707
19,285
25,952
24,762
25,643
22,207
20,455
15,527
20,519
17,088
11,456
20,542
17,400
26,764
21,474
14,805
13,673
9,925
19,521
14,313
9,254
5,942
53,466
48,234
63,560
72,253
81,912
82,032
77,829
72,019
116,330
111,815
108,910
94,522
91,276
82,978
76,677
84,057
86,037
78,660
72,904
72,90478,66086,03784,05776,67782,97891,27694,522108,910111,815116,33072,01977,82982,03281,91272,25363,56048,23453,4665,9429,25414,31319,5219,92513,67314,80521,47426,76417,40020,54211,45617,08820,51915,52720,45522,20725,64324,76225,95219,2856,70711,75114,6715,8785,5333,9905,6503,2405,6192,567000000000122222222660000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
6
0
0
0
11
11
19
11
35
35
35
35
35
0
0
0
0
40
40
40
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000004040400000353535353511191111000600000000000000000000000000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
238
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
56
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000000056000000000000000000000002380000000000000000000000
       Other Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
35
0
0
0
0
0
0
258
0
0
334
234
169
53
218
668
608
672
689
623
238
146
838
972
957
1,593
1,871
1,031
1,010
673
439
884
610
351
656
340
424
238
48
864
1,042
946
1,365
1,494
1,259
1,229
1,920
2,034
1,967
1,608
2,032
4,024
4,261
2,618
1,586
1,316
1,031
860
1,602
1,6028601,0311,3161,5862,6184,2614,0242,0321,6081,9672,0341,9201,2291,2591,4941,3659461,042864482384243406563516108844396731,0101,0311,8711,593957972838146238623689672608668218531692343340025800000035000000000000000
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
3
3
3
0
7
14
14
168
176
162
136
121
130
106
165
160
141
138
126
511
506
498
493
500
546
560
1,970
1,874
1,767
1,583
1,558
1,450
1,347
1,472
1,350
1,283
1,218
639
509
3,503
3,393
3,250
3,480
3,514
3,348
3,182
2,979
2,793
2,594
2,393
2,3932,5942,7932,9793,1823,3483,5143,4803,2503,3933,5035096391,2181,2831,3501,4721,3471,4501,5581,5831,7671,8741,970560546500493498506511126138141160165106130121136162176168141470333010000000000000000000000
       Property Plant Equipment 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
3
3
3
0
7
14
14
133
141
128
101
86
95
106
116
110
91
89
76
70
66
57
52
59
105
119
1,529
1,433
1,326
1,142
1,117
1,009
906
1,031
908
841
776
639
509
3,204
3,093
2,948
3,176
3,207
3,038
2,869
2,663
2,475
2,272
2,069
2,0692,2722,4752,6632,8693,0383,2073,1762,9483,0933,2045096397768419081,0319061,0091,1171,1421,3261,4331,52911910559525766707689911101161069586101128141133141470333010000000000000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
50
50
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000505000000000000000000000000000000000000000000000000000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-1
0
0
0
0
0
0
0
0
35
34
34
35
34
35
0
49
50
50
50
50
441
441
441
441
441
441
441
441
441
441
441
441
441
1,260
1,160
442
442
442
0
0
299
300
302
304
307
0
0
0
0
0
0
000000307304302300299004424424421,1601,2604414414414414414414414414414414414414415050505049035343534343500000000-10000000000000000000000
> Total Liabilities 
0
19
19
23
35
40
56
65
69
76
81
85
89
98
106
111
86
95
99
78
82
84
94
100
104
4,643
2,806
3,820
3,446
7,325
20,028
11,117
10,226
9,492
3,611
3,051
2,155
4,614
3,286
2,488
3,028
4,521
5,370
4,106
3,529
4,666
6,393
5,266
4,122
6,077
6,892
6,118
6,382
6,026
5,344
5,184
5,100
5,078
4,361
3,955
4,194
6,843
5,725
43,619
45,561
47,711
44,818
45,974
45,361
45,066
44,495
46,026
43,906
44,141
44,14143,90646,02644,49545,06645,36145,97444,81847,71145,56143,6195,7256,8434,1943,9554,3615,0785,1005,1845,3446,0266,3826,1186,8926,0774,1225,2666,3934,6663,5294,1065,3704,5213,0282,4883,2864,6142,1553,0513,6119,49210,22611,11720,0287,3253,4463,8202,8064,64310410094848278999586111106988985817669655640352319190
   > Total Current Liabilities 
0
4
4
2
4
4
17
23
22
26
21
25
24
30
33
36
33
36
36
25
28
26
30
29
31
4,643
2,806
3,820
3,446
7,325
20,028
11,117
10,226
9,492
3,611
3,051
2,155
4,614
3,286
2,488
3,028
4,521
5,370
4,106
3,529
4,666
6,393
5,266
4,122
6,063
5,855
5,178
5,541
5,344
4,710
4,656
4,680
4,767
4,164
3,873
4,190
6,840
5,723
6,282
8,350
10,628
7,864
9,151
8,672
8,494
8,064
9,728
7,755
8,148
8,1487,7559,7288,0648,4948,6729,1517,86410,6288,3506,2825,7236,8404,1903,8734,1644,7674,6804,6564,7105,3445,5415,1785,8556,0634,1225,2666,3934,6663,5294,1065,3704,5213,0282,4883,2864,6142,1553,0513,6119,49210,22611,11720,0287,3253,4463,8202,8064,64331293026282536363336333024252126222317442440
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
124
0
0
140
75
37
0
158
94
55
8,217
284
190
92
1,228
266
178
90
432
301
576
426
54
16
7
0
0
249
537
477
410
381
669
564
457
854
874
894
834
614
390
622
780
996
506
1,028
1,044
1,082
551
1,102
560
580
5805601,1025511,0821,0441,0285069967806223906148348948748544575646693814104775372490071654426576301432901782661,228921902848,217559415803775140001240000000000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
284
0
0
0
266
0
0
0
301
576
426
54
16
7
0
0
0
175
101
25
381
268
154
38
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000381542683812510117500071654426576301000266000284000000000000000000000000000000000
       Accounts payable 
0
4
4
-4
0
2
9
10
10
12
10
12
10
14
12
11
12
14
11
25
2
0
1
0
577
897
460
794
688
379
615
1,045
1,731
2,284
1,248
1,011
888
1,474
1,853
1,379
2,571
4,195
4,019
2,880
2,700
4,650
5,636
5,266
4,122
5,814
5,318
4,701
5,131
4,598
4,041
4,092
4,223
4,340
3,727
3,426
3,773
5,535
5,261
5,767
7,869
10,130
7,358
8,637
8,150
7,953
7,513
9,177
0
0
009,1777,5137,9538,1508,6377,35810,1307,8695,7675,2615,5353,7733,4263,7274,3404,2234,0924,0414,5985,1314,7015,3185,8144,1225,2665,6364,6502,7002,8804,0194,1952,5711,3791,8531,4748881,0111,2482,2841,7311,045615379688794460897577010225111412111214101210121010920-4440
       Other Current Liabilities 
0
1
1
2
4
1
8
14
12
14
11
13
14
16
21
25
20
22
24
25
27
26
29
29
-545
3,606
2,272
2,989
2,758
6,788
19,318
10,016
8,495
6,924
2,173
1,948
1,267
2,874
1,255
1,020
457
326
1,351
1,226
829
16
757
0
0
6,063
5,318
4,701
5,131
365
0
0
4,261
-427
-437
-447
-417
691
72
-311
-390
-498
7,358
-514
-522
-541
-35,000
-551
7,195
7,568
7,5687,195-551-35,000-541-522-5147,358-498-390-31172691-417-447-437-4274,261003655,1314,7015,3186,06300757168291,2261,3513264571,0201,2552,8741,2671,9482,1736,9248,49510,01619,3186,7882,7582,9892,2723,606-54529292627252422202521161413111412148142110
   > Long-term Liabilities 
0
15
15
21
31
36
39
42
47
50
60
60
65
69
73
75
54
59
63
54
54
58
64
71
73
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
13
1,037
940
841
682
634
528
420
311
197
82
4
3
2
37,337
37,211
37,083
36,954
36,823
36,689
36,572
36,431
36,298
36,151
35,993
35,99336,15136,29836,43136,57236,68936,82336,95437,08337,21137,337234821973114205286346828419401,037130000000000000000000000007371645854546359547573696560605047423936312115150
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
13
211
191
171
151
130
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000130151171191211130000000000000000000000000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
35,000
35,000
35,000
35,000
35,000
0
0
0
0
0
0
00000035,00035,00035,00035,00035,000000000000000000000000000000000000000000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
35,000
35,000
0
35,000
35,000
0
0
0
0
0
0
00000035,00035,000035,00035,000000000000000000000000000000000000000000000000000000000000000000
> Total Stockholder Equity
0
-18
-18
-22
-29
-33
-54
-63
-66
-74
-79
-83
-87
-96
-105
-76
-86
-95
-99
-78
-82
-84
-94
-100
-104
1,146
551
1,915
604
-1,560
-13,468
4,330
2,372
-1,923
16,444
23,280
22,894
21,974
20,058
19,084
14,234
18,008
12,875
8,871
18,192
13,671
21,748
17,318
11,580
8,813
5,343
15,700
9,936
5,644
3,020
50,774
45,427
61,319
70,736
80,499
80,285
73,545
68,837
78,181
71,255
66,481
57,208
53,077
43,583
36,379
43,857
43,835
38,208
32,758
32,75838,20843,83543,85736,37943,58353,07757,20866,48171,25578,18168,83773,54580,28580,49970,73661,31945,42750,7743,0205,6449,93615,7005,3438,81311,58017,31821,74813,67118,1928,87112,87518,00814,23419,08420,05821,97422,89423,28016,444-1,9232,3724,330-13,468-1,5606041,9155511,146-104-100-94-84-82-78-99-95-86-76-105-96-87-83-79-74-66-63-54-33-29-22-18-180
   Common Stock
0
23
0
23
23
23
23
23
23
23
23
23
23
112
112
112
112
112
112
112
112
112
112
112
112
214
214
236
237
25
26
28
30
30
36
40
42
44
45
47
48
56
57
59
80
80
110
110
110
116
119
162
165
165
175
13
14
18
19
21
22
22
22
25
25
26
26
27
27
28
29
31
31
31
313131292827272626252522222221191814131751651651621191161101101108080595756484745444240363030282625237236214214112112112112112112112112112112112112232323232323232323230230
   Retained Earnings Total Equity000000-314,983-299,8020-278,118-268,644-260,877-255,748-247,738-241,315-236,294-230,974-224,594-219,054-214,428-208,758-204,155-197,556-192,528-186,857-180,537-174,389-169,467-163,153-157,990-151,667-144,613-136,552-129,856-123,257-116,633-112,230-105,690-101,743-94,280-91,205-85,779-797,017-83,217-66,51700000000-257-2540000000000000000000
   Accumulated Other Comprehensive Income 00000000000000-339-3140-272-260-237-237-225-211-198-266-254-240-228-216-217-206-191-170-151-131-111-93-83-66-50-39-25-11-3-2-154-154-154-55,7430000000000000000000000000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
64
64
0
0
0
0
0
0
0
0
64,933
69,723
84,004
88,121
89,252
110,688
124,982
128,542
134,160
136,647
142,294
144,042
154,504
157,431
160,479
176,102
176,744
191,104
191,597
192,007
195,554
197,751
213,094
213,926
214,237
217,273
269,815
270,007
292,275
307,011
321,793
328,001
329,271
329,692
346,800
349,348
0
356,984
368,033
0
0
0
0
0
0
000000368,033356,9840349,348346,800329,692329,271328,001321,793307,011292,275270,007269,815217,273214,237213,926213,094197,751195,554192,007191,597191,104176,744176,102160,479157,431154,504144,042142,294136,647134,160128,542124,982110,68889,25288,12184,00469,72364,9330000000064640000000000000000000
   Treasury Stock00000000000000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
152
175
175
175
185
175
175
175
175
175
175
175
175
175
175
175
64
175
64
64
64
175
175
64
112,611
56,769
60,896
61,005
64,935
69,723
84,004
88,121
89,252
110,688
124,982
128,542
134,160
136,647
142,294
144,042
154,504
157,431
160,479
176,102
176,744
191,104
191,597
192,007
195,554
197,751
213,094
213,926
0
217,273
269,815
270,007
292,275
307,011
321,793
328,001
329,271
329,692
346,800
349,348
355,220
356,984
368,033
371,815
373,934
390,081
401,410
407,351
408,553
408,553407,351401,410390,081373,934371,815368,033356,984355,220349,348346,800329,692329,271328,001321,793307,011292,275270,007269,815217,2730213,926213,094197,751195,554192,007191,597191,104176,744176,102160,479157,431154,504144,042142,294136,647134,160128,542124,982110,68889,25288,12184,00469,72364,93561,00560,89656,769112,61164175175646464175641751751751751751751751751751751751851751751751520



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.




5.5. Income Statements

Currency in USD. All numbers in thousands.


5.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue0
Cost of Revenue-0
Gross Profit00
 
Operating Income (+$)
Gross Profit0
Operating Expense-42,121
Operating Income-42,121-42,121
 
Operating Expense (+$)
Research Development30,045
Selling General Administrative12,076
Selling And Marketing Expenses0
Operating Expense42,12142,121
 
Net Interest Income (+$)
Interest Income3,878
Interest Expense-0
Other Finance Cost-0
Net Interest Income3,878
 
Pretax Income (+$)
Operating Income-42,121
Net Interest Income3,878
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-38,243-45,999
EBIT - interestExpense = 0
-38,243
-38,243
Interest Expense0
Earnings Before Interest and Taxes (EBIT)0-38,243
Earnings Before Interest and Taxes (EBITDA)-42,121
 
After tax Income (+$)
Income Before Tax-38,243
Tax Provision-0
Net Income From Continuing Ops-38,243-38,243
Net Income-38,243
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net3,878-3,878
 

Technical Analysis of Actinium Pharmaceuticals Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Actinium Pharmaceuticals Inc. The general trend of Actinium Pharmaceuticals Inc is BULLISH with 14.3% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Actinium Pharmaceuticals Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (14.3%) Bearish trend (-14.3%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Actinium Pharmaceuticals Inc Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Actinium Pharmaceuticals Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 2.01 < 2.28 < 2.41.

The bearish price targets are: 1.13 > 1.0292.

Know someone who trades $ATNM? Share this with them.πŸ‘‡

Actinium Pharmaceuticals Inc Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Actinium Pharmaceuticals Inc. The current mas is .

The long score for the Moving Averages is 8/14.
The longshort score for the Moving Averages is 2/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Actinium Pharmaceuticals Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Actinium Pharmaceuticals Inc. The current macd is 0.0341546.

The long score for the Moving Average Convergence/Divergence (MACD) is 4/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 4/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Actinium Pharmaceuticals Inc price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Actinium Pharmaceuticals Inc. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Actinium Pharmaceuticals Inc price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Actinium Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) ChartActinium Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Actinium Pharmaceuticals Inc. The current adx is 20.44.

The long score for the Directional Movement Index (DMI) is 2/7.
The longshort score for the Directional Movement Index (DMI) is 2/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Actinium Pharmaceuticals Inc shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bullish trend could be forming. +1
Actinium Pharmaceuticals Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Actinium Pharmaceuticals Inc. The current sar is 1.20269494.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Actinium Pharmaceuticals Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Actinium Pharmaceuticals Inc. The current rsi is 60.61. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending up: The RSI is trending up. +1
Actinium Pharmaceuticals Inc Daily Relative Strength Index (RSI) ChartActinium Pharmaceuticals Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Actinium Pharmaceuticals Inc. The current phase is Overbought in bull market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH > 80: The STOCH %K is above 80 and overbought. +2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Actinium Pharmaceuticals Inc price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Actinium Pharmaceuticals Inc Daily Stochastic Oscillator ChartActinium Pharmaceuticals Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Actinium Pharmaceuticals Inc. The current cci is 224.97.

The long score for the Commodity Channel Index (CCI) is 1/1.
The longshort score for the Commodity Channel Index (CCI) is 1/(-1 +1).

  • CCI > 100: The CCI is above 100, it indicates that the price is significantly above its average, suggesting a potential overbought condition. +1
Actinium Pharmaceuticals Inc Daily Commodity Channel Index (CCI) ChartActinium Pharmaceuticals Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Actinium Pharmaceuticals Inc. The current cmo is 32.19.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Actinium Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) ChartActinium Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Actinium Pharmaceuticals Inc. The current willr is -18.94736842.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
Actinium Pharmaceuticals Inc Daily Williams %R ChartActinium Pharmaceuticals Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of Actinium Pharmaceuticals Inc.

Actinium Pharmaceuticals Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Actinium Pharmaceuticals Inc. The current atr is 0.16207442.

Actinium Pharmaceuticals Inc Daily Average True Range (ATR) ChartActinium Pharmaceuticals Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Actinium Pharmaceuticals Inc. The current obv is 5,386,529.

Actinium Pharmaceuticals Inc Daily On-Balance Volume (OBV) ChartActinium Pharmaceuticals Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Actinium Pharmaceuticals Inc. The current mfi is 70.12.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Actinium Pharmaceuticals Inc Daily Money Flow Index (MFI) ChartActinium Pharmaceuticals Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Actinium Pharmaceuticals Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-12-09SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-12-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-12CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-12-13SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-12-16MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-17STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-12-18CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-12-19MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-12-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-12-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-26STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-12-27STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-12-30CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-12-31STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-02DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-01-03CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-01-07STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-10DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-01-14SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-01-16WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-01-17DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-01-21STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-23STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-24STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-01-28STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-29STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-30MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-03STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-06STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-10STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-11STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-12MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-02-13STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-02-18MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-19STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-20STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-02-21STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-02-24DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-02-25DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-02-26SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-27MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-02-28MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-03MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-04STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-05MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-06CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-07STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-11STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-03-13WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-03-14CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-03-17BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-18STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-20STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-21ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-03-24RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-03-25MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-03-26ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-28STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-31SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2025-04-03MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-09DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-10STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-04-11STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-04-14DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-04-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-04-16STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-17MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-04-21STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-23SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-04-24STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-25STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-04-28CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-04-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-04-30WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-05-02STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.

6.3. Candlestick Patterns

Actinium Pharmaceuticals Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Actinium Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5060.606
Ma 20Greater thanMa 501.311
Ma 50Greater thanMa 1001.316
Ma 100Greater thanMa 2001.280
OpenGreater thanClose1.550
Total2/5 (40.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Actinium Pharmaceuticals Inc with someone you think should read this too:
  • Are you bullish or bearish on Actinium Pharmaceuticals Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Actinium Pharmaceuticals Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Actinium Pharmaceuticals Inc

I send you an email if I find something interesting about Actinium Pharmaceuticals Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Actinium Pharmaceuticals Inc.

Receive notifications about Actinium Pharmaceuticals Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.